CAS No.54143-56-5,FLECAINIDE ACETATE Suppliers,MSDS download

Products Categories

Pharmaceutical (59)
Others (15)
Organic Chemicals (10)
Materials (2)
Reagent (1)

Basic Information

Molecular Structure:
CAS No.:	54143-56-5
Name:	FLECAINIDE ACETATE
Article Data:	5

Formula:	C₁₉H₂₄F₆N₂O₅
Molecular Weight:	474.4
Synonyms:	R-818;2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidinylmethyl)benzamide acetate;Flecainide acetate;N-(2-Piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate;54143-55-4;FLECAINIDE MONOACETATE;R 818;Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate;Tambocor;Flecainide acetate [USAN:JAN];Benzamide,N-(2-piperidinylmethyl)-2,5-bis(2,- 2,2-trifluoroethoxy)-,monoacetate;N-(Piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate;Tambocor (TN);acetic acid; N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide;Flecainide acetate (JAN/USP);? Flecainide acetate;
EINECS:	258-997-5
Density:	1.286 g/cm³
Melting Point:	145-147℃
Boiling Point:	434.9 °C at 760 mmHg
Flash Point:	216.8 °C
Solubility:	Soluble in dilute acetic acid, dimethyl sulfoxide, ethanol, methanol and water.
Hazard Symbols:	Xn
Risk Codes:	22-36/37/38-63
Safety:	22-26-36/37/39-45
PSA:	96.89000
LogP:	4.25130

Total:85 Page 1 of 3 1 2 3 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 54143-56-5

Specification

The Flecainide acetate, with the CAS registry number 54143-56-5, is also known as 2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidinylmethyl)benzamide acetate. It belongs to the product category of Organics. Its EINECS registry number is 258-997-5. This chemical's molecular formula is C₁₉H₂₄F₆N₂O₅ and molecular weight is 474.39. Its IUPAC name is called acetic acid; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide. This chemical's classification codes are Cardiac Depressant (anti-arrhythmic); Human Data; Reproductive Effect. Flecainide acetate is a class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias. It is used to treat a variety of cardiac arrhythmias including paroxysmal atrial fibrillation, paroxysmal supraventricular tachycardia, and ventricular tachycardia.

Physical properties of Flecainide acetate: (1)ACD/LogP: 2.90; (2)ACD/LogD (pH 5.5): -0.19; (3)ACD/LogD (pH 7.4): 0.19; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1.76; (8)#H bond acceptors: 5; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 7; (11)Flash Point: 216.8 °C; (12)Enthalpy of Vaporization: 69.11 kJ/mol; (13)Boiling Point: 434.9 °C at 760 mmHg; (14)Vapour Pressure: 9.11E-08 mmHg at 25°C.

When you are using this chemical, please be cautious about it as the following:
This chemical may cause damage to health. It is harmful if swallowed. In addition, it is irritating to eyes, respiratory system and skin. You should not breathe its dust. Whenever you will contact it, please wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)C.FC(F)(F)COc2cc(C(=O)NCC1NCCCC1)c(OCC(F)(F)F)cc2
(2)InChI: InChI=1/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)
(3)InChIKey: RKXNZRPQSOPPRN-UHFFFAOYAP

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	50mg/kg (50mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 33, Pg. 2427, 1991.
dog	LDLo	unreported	15mg/kg (15mg/kg)	CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE	Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 1714, 1999.
man	LDLo	multiple routes	25mg/kg/1W-I (25mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)	American Journal of Cardiology. Vol. 53, Pg. 329, 1984.
man	LDLo	oral	22989ug/kg (22.989mg/kg)	CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION	Forensic Science International. Vol. 106, Pg. 115, 1999.
man	TDLo	intravenous	1714ug/kg/4M- (1.714mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)	American Heart Journal. Vol. 107, Pg. 222, 1984.
man	TDLo	multiple routes	26mg/kg/89H-I (26mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"	Postgraduate Medical Journal. Vol. 62, Pg. 61, 1986.
man	TDLo	oral	40mg/kg/2W-I (40mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	Annals of Internal Medicine. Vol. 111, Pg. 107, 1989.
mouse	LD50	intravenous	23800ug/kg (23.8mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
mouse	LD50	oral	170mg/kg (170mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
mouse	LD50	subcutaneous	188mg/kg (188mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
rat	LD50	intravenous	16200ug/kg (16.2mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
rat	LD50	oral	1346mg/kg (1346mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
rat	LD50	subcutaneous	215mg/kg (215mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
women	TDLo	oral	20mg/kg (20mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	American Journal of Emergency Medicine. Vol. 16, Pg. 534, 1998.
women	TDLo	oral	28mg/kg/1W-I (28mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE	British Medical Journal. Vol. 291, Pg. 450, 1985.
women	TDLo	oral	40mg/kg (40mg/kg)	CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	British Journal of Clinical Practice. Vol. 49, Pg. 218, 1995.
women	TDLo	oral	50mg/kg (50mg/kg)	CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE	Connectical Medicine. Vol. 54, Pg. 183, 1990.
women	TDLo	oral	56mg/kg/1W-I (56mg/kg)	CARDIAC: OTHER CHANGES	American Journal of Cardiology. Vol. 55, Pg. 1643, 1985.
women	TDLo	oral	76mg/kg (76mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	Annals of Internal Medicine. Vol. 106, Pg. 807, 1987.
women	TDLo	oral	160mg/kg (160mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: CHANGE IN RATE	Medical Journal of Australia. Vol. 155, Pg. 349, 1991.